SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
HONG KONG, Nov 26, 2021 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab", or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, was invited to attend the inaugural Asia Summit On Global Health ("ASGH"), jointly organized by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC) yesterday, Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, joined the panel discussion on the topic of "What's Next for Healthcare Innovation and Investment".
| The panel discussion of "What's Next for Healthcare Innovation and Investment";
Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company (second right) |
| Dr. Shui On LEUNG was the guest speaker |
With the theme of "Shaping a Resilient and Sustainable Future", the Inaugural ASGH was held at the Convention Hall of Hong Kong Convention and Exhibition Centre and synchronized online. At the panel discussion with the topic of "What's Next for Healthcare Innovation and Investment", Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of the Company, was one of the guest speakers.
Regarding the development of biotechnology and healthcare ecosystem in Hong Kong in recent years, Dr. Shui On LEUNG said that in stead of being a standalone ecosystem, Hong Kong has to merge with either mainland China or other part of the world, and Hong Kong can play the role as a phase I clinical trial center and a trial site. He said that the ecosystem depends on scientific innovation and government involvement. Doing innovative research in Hong Kong enjoys advantages such as legal protection and patenting system, which will facilitate the companies to get licensed with other collaborators. He pointed out that Chapter 18A of the Listing Rules and Guidelines reflects the value of the biotechnology industry, improves market liquidity, and encourages more investment into the biotechnology system.
More than 70 senior government officials, investors, influential business leaders, financial and professional service providers as well as renowned academia from related sectors worldwide were invited to attend the summit to exchange insights and explore business opportunities and partnership. Exhibitions, project pitching and business networking sessions were also be staged to facilitate business negotiation and investment partnerships.
Dr. Shui On LEUNG said, "It is a great honour to attend the Inaugural ASGH on behalf of the Company. Through the communication and sharing with stakeholders including healthcare and technology experts, research and business leader, start-ups, investors and government decision-maker on the summit, the overall development of the ecosystem for the healthcare and biotechnology sectors will be benefited. SM03, the flagship product of the Company, completed the enrolment for Phase 3 clinical trial in this year and expected to readout data next year, indicating that SM03 will soon be commercialized. For business development, we have entered into our first license agreement in September this year. To enhance our R&D and product development capabilities, new plant of over 32,000 liters production capacity of our Suzhou campus is under construction. In the future, the Company will be dedicated to discovering and developing novel drug targets and exploring treatments for immunological diseases, further expanding our product pipeline to fight for patients' well-being. We will also continue to actively looking for opportunities of collaboration and partnership, consolidate the capital market position of the Company as well as contribute to human healthcare and the biotechnology industry of Hong Kong."
About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgar, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.
Source: SinoMab BioScience Limited Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture Mar 29, 2024 15:19 JST
| Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 Mar 29, 2024 14:32 JST
| TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants Mar 29, 2024 11:00 JST
| Fujitsu Selected as CDP Supplier Engagement Leader Mar 29, 2024 10:28 JST
| Mazda Production and Sales Results for February 2024 Mar 29, 2024 10:00 JST
| Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System Mar 28, 2024 16:45 JST
| Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan Mar 28, 2024 13:52 JST
| Toyota Releases Sales, Production, and Export Results for February 2024 Mar 28, 2024 13:35 JST
| TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants Mar 28, 2024 03:00 JST
| PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles Mar 27, 2024 15:13 JST
| NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System Mar 27, 2024 15:00 JST
| TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building Mar 27, 2024 03:00 JST
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry Mar 26, 2024 19:04 JST
| La Banque Postale and JCB join forces to elevate payments experience for travellers in France Mar 26, 2024 15:00 JST
| Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin' Mar 26, 2024 10:24 JST
| NEC develops marketing strategy planning & effectiveness simulation technology using generative AI Mar 25, 2024 10:08 JST
| Toyota to Open New Tokyo Head Office in Shinagawa in FY2030 Mar 22, 2024 16:15 JST
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year Mar 22, 2024 16:04 JST
| Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle Mar 22, 2024 15:34 JST
| JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card Mar 22, 2024 15:00 JST
|
More Latest Release >>
|